~ Pfizer commits $100,000 to each winner and launches new partnership
awards for 2013 ~
MONTREAL, May 8, 2013 /CNW/ - Pfizer Canada is pleased to announce the
second round of recipients of the Psychiatry Research Awards Program.
The program, launched in May 2011, was developed to advance clinical
research and patient care in psychiatry by supporting Canadian
investigators in their research efforts.
Dr. Rajamannar Ramasubbu, MD, Associate Professor, Hotchkiss Brain Institute, University of
Calgary and Dr. Jorge Armony, PhD, Douglas Mental Health University Institute, McGill University will
each receive $100,000 to support their research in psychiatric
"This award represents a major advance towards improving treatment
outcomes for major depression. The current trial-and-error approach
delays recovery and causes significant side effects," says Dr.
Ramasubbu, who is researching prediction of individual treatment
response based on brain changes at the early phase of antidepressant
treatment. "By working towards an individualized and personalized
model, we hope to ensure early intervention so patients are matched
with the right medication early on."
The Psychiatry Research Awards Program is a competitive research grant
program open to all researchers interested in psychiatric diseases
including physicians and academics.
"It is an honor to receive this award. The research we're doing is
helping us better understand emotional disorders and seek more
effective treatments," says Dr. Armony, who is conducting research on
how the brain detects, analyzes and responds to environmental events
with affective value and how these processes can affect those living
with bipolar disorder. "Better understanding the neural basis of
emotion might eventually lead to new mood stabilizer treatments and
therapies for this disorder."
Submitted proposals are reviewed by an independent external review
committee, chaired by Dr. Glenda MacQueen, MD, PhD, FRCPC, Professor at
the Department of Psychiatry, University of Calgary, Calgary, Alberta.
"This year's submissions to the Pfizer Psychiatry Research Awards
Program showcase the quality of mental health research that is
happening across the country," says Dr. MacQueen. "This research makes
a difference to Canadians in so many different areas, so to recognize
the outstanding work of remarkable Canadian researchers driving
world-class research is truly an honour."
2013 Request for Proposals
Pfizer is now accepting proposals for the 2013 round, which includes
five new awards with the support of its program sponsors. The 2013
Pfizer Canada Major Depressive Disorders Research Award
Pfizer Canada Geriatric Anxiety Research Award
Hotchkiss Brain Institute/Pfizer Canada Research Award
Healthy Minds Canada/Sun Life Financial/Pfizer Canada Research Award
Institut Universitaire en Santé Mental de Montréal (IUSMM)/Pfizer Canada
"With the addition of these exciting new partnership awards, Pfizer
Canada can expand its support for research that will improve the mental
health and well-being of Canadians," says Dr. Bernard Prigent, Vice
President and Medical Director, Pfizer Canada. "We are proud of the
accomplishments of our 2012 recipients, and look forward to continued
success in the coming year."
The Psychiatry Research Awards Program is the most recent initiative in
Pfizer's ongoing commitment to mental illness in Canada. Additional
information and application information can be found at www.PfizerCNS.ca. The submission deadline for the 2013 competition is October 1, 2013.
Mental Illness in Canada
One in five Canadians will personally experience a mental illness during
their lifetime.1 Mental illnesses can affect people of all ages, educational and income
levels, and cultures2 and are the result of a complex interplay of genetic, biological,
personality and environmental factors.3
Nearly three million Canadians will experience depression in their
lifetime,4 with most people being affected between the ages of 24 and 44.5 A major depressive disorder can occur once in a lifetime, or episodes
can be recurrent.6
The disorder also has an impact in the workplace, with 1 in 20 employees
experiencing depression at any given time.7 The consequences of undiagnosed depression include decreased
productivity, inability to concentrate and frequent 'sick' days.8
Five to 10 per cent of those aged 65 and older are suffering from
anxiety disorder, a condition which often affects daily functioning and
becomes a significant source of distress.9 The prevalence of anxiety in seniors is even higher for those living in
institutions such as retirement homes.1
About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the
world's leading biopharmaceutical companies. Our diversified health
care portfolio includes some of the world's best known and most
prescribed medicines and vaccines. At Pfizer, we're working together
for a healthier world. For more information, visit www.pfizer.ca.
About Our Award Partners
Hotchkiss Brain Institute
The Hotchkiss Brain Institute at the University of Calgary is dedicated
to advancing neurological and mental health research and education. The
Institute's research strengths in foundational neuroscience are leading
to new treatments for neurological and psychiatric disorders, aimed at
improving quality of life and patient care. More information on the
Hotchkiss Brain Institute can be found at www.hbi.ucalgary.ca.
Healthy Minds Canada
Healthy Minds Canada (HMC) is a national charitable organization that
was founded in 1980 and since this time has funded close to 400
research projects at 42 universities and teaching hospitals across
Canada. In addition to funding the best mental health and addiction
research in Canada, HMC hosts workshops and symposia across the country
and publishes resources and tools to translate the outcomes of mental
health and addiction research and deliver this valuable information to
those who need it the most.
Sun Life Financial
Sun Life Financial is a leading international financial services
organization providing a diverse range of protection and wealth
accumulation products and services to individuals and corporate
customers. Chartered in 1865, Sun Life Financial and its partners today
have operations in key markets worldwide, including Canada, the United
States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan,
Indonesia, India, China, Vietnam and Bermuda. As of September 30, 2012,
the Sun Life Financial group of companies had total assets under
management of $515 billion. For more information please visit www.sunlife.com. Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE)
and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Institut Universitaire en Santé Mental de Montréal
The Institute provides specialized and ultra-specialized services in
mental health. As a leader in its field, the hospital develops
knowledge through research, teaching, and assessment. The Institut
universitaire en santé mentale de Montréal is a member of the
Université de Montréal excellence in health network. www.iusmm.ca
SOURCE: Pfizer Canada Inc.
For further information:
or to arrange an interview with one of the award recipients and/or Dr. MacQueen, please contact:
Tel: 1-866-9PFIZER (973-4937)